




Differential Diagnosis	
Signs/symptoms/Hx Elements	DDx
Hypercarbia	ICI-associated myasthenia gravis
SVT, shock, volume overload	ICI-associated myocarditis
Risk factors for TB	ICI-associated reactivation of TB
Recent cytotoxic chemotherapy	DAH, opportunistic infections
Recent high-dose steroid (for brain/spine metastasis, etc)	PJP, nocardia, other opportunistic infections
Recent XRT	Radiation pneumonitis
Increase in tumor size	Pseudo-progression

	Severity grading for pulmonary irAE		
	CTCAE Grade	Clinical Presentation	
	1	Asymptomatic, radiographic changes only	
	2	Symptomatic, not interfering with ADL	
	3	Symptomatic, interfering with ADL or with new oxygen requirement	
	4	Life-threatening, requiring ventilator support	
	5	Death	
		Michot JM, Bigenwald C, Champiat S, et al. Eur J Cancer 2016;54:139–4 https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ QuickReference_5x7.pdf	
9			











Ground glass opacities (37%)

Discrete focal increased attenuation Preserved bronchovascular markings

J Clin Oncol. 2017 Mar;35(7):709-717







Cryptogenic organizing pneumonia-like (19%)

Discrete patchy or confluent consolidation with/without air bronchograms. Predominantly peripheral or subpleural distribution

J Clin Oncol. 2017 Mar;35(7):709-717







	Severity grading and for pulmon	
CTCAE Grade	Clinical Presentation	Fate of Immunotherapy
1	Asymptomatic, radiographic changes only	Cautiously continue
2	Symptomatic, not interfering with ADL	Suspend, temporarily
3	Symptomatic, <u>interfering with ADL</u> or with new oxygenation requirement	Suspend, and likely discontinue
4	Life-threatening, requiring ventilator support	Discontinue permanently
5		Death
	https://	JM, Bigenwald C, Champiat S, et al. Eur J Cancer 2016 evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_ Reference_5x7.pdf

Severity grading and management recommendations for pulmonary irAE				
	Grade	Symptoms	Management	
	1	Asymptomatic, radiographic changes only 1 lobe or < 25%	Hold ICPi with radiographic evidence of pneumonitis progression Monitor patients weekly with history and PE and pulse oximetry; may also offer CXR May offer one repeat CT in 3-4 weeks; A repeat spirometry/DLCO in 3-4 weeks May resume ICPi with radiographic evidence of improvement or resolution. If no improvement, should treat as G2	

reco		ns for pulmonary irAE
Grade	Symptoms	Management
2 more t 2 25% medic indic	omatic, involves han one lobe of he lung or 6-50% of lung arenchyma, cal intervention cated, limiting rumental ADL	Hold ICPi until resolution to G1 or less Prednisone 1-2 mg/kg/d and taper by 5-10 mg/wk over 4-6 weeks Consider bronchoscopy with BAL Consider empirical antibiotics Monitor every 3 days with history and physical examination and pulse oximetry, consider CXR; No clinical improvement after 48-72 hours of prednisone, treat as G3

	recommendations for pulmonary irAE		
Grade	Symptoms	Management	
3-4	G3: Severe symptoms, hospitalization required, involves all lung lobes or >50% of lung parenchyma, limiting self-care ADL, oxygen indicated	Permanently discontinue ICPi Empirical antibiotics; (methyl)prednisolone IV 1-2 mg/kg/d <u>;</u> No improvement after 48 hours, may add infliximab 5 mg/kg or mycophenolate mofetil IV 1 g twice a day or IVIG for 5 days or cyclophosphamide	
G4: Life-threatening respiratory compromise, urgent intervention indicated (intubation)	Taper corticosteroids over 4-6 weeks Pulmonary and infectious disease consults if necessary Bronchoscopy with BAL +/- transbronchial biopsy Patients should be hospitalized for further management		

